BrainsWay Ltd · TASE:BWAY

BrainsWay — Investor Presentation (November 2026)

20 slides from BrainsWay's investor presentation, Nov 10, 2026

  1. Slide 1: Leading the next phase of interventional psychiatry

    Slide 1: Leading the next phase of interventional psychiatry

    Leading the next phase of interventional psychiatry Technology. Evidence. Scale. Growth. N o v e m b e r 2026 I N V E S T O R D E C K | Nasdaq / TASE: BWAY

  2. Slide 2: Disclaimer: Safe Harbor and Non-GAAP/IFRS Financial Measures

    Slide 2: Disclaimer: Safe Harbor and Non-GAAP/IFRS Financial Measures

    D I S C L A I M E R Investor Deck | November 2026 2 Safe Harbor and Non - GAAP/IFRS Financial Measures T h i s p r es e n t a t i o n do e s n o t c on s t i tut e a n o ff e r o r i n v i t a t i o n t o se l l o r iss u e , o r a n y s o li c i t a t i o n o f a n o ff e r t o s ub s c ri b e f o

  3. Slide 3: Q3 2026 Highlights

    Slide 3: Q3 2026 Highlights

    Q3 2026 Highlights G R O W T H & P R O F I T A B I L I T Y +34% Revenue Growth $18.1m · vs $13.5m Q3 - 2025 +107% Operating Income $2.6m · vs $1.3m Q3 - 2025 +92% EBITDA $3.9m · vs $2.0m Q3 - 2025 F I N A N C I A L S $63.4m Cash Balance $62.4m Q2 - 2026 $85m Backlog +31% $65m Q3 - 2025 $21.3m Collec

  4. Slide 4: Interventional Psychiatry Has Reached an Inflection Point

    Slide 4: Interventional Psychiatry Has Reached an Inflection Point

    W H Y N O W Interventional Psychiatry Has Reached an Inflection Point Interventional psychiatry is one of healthcare’s fastest - growing categories - and BrainsWay is its clear market leader . 8.5M+ Deep TMS sessions delivered 1 Proven, growing clinical demand across indications. 300M+ Covered lives

  5. Slide 5: Not All TMS is the Same

    Slide 5: Not All TMS is the Same

    Investor Deck | November 2026 W H Y B R A I N S W A Y W I N S Not All TMS is the Same 4 FDA indications Only Deep TMS platform cleared across four. 8.5M+ Sessions delivered Real - world scale competitors cannot match. The Leader In the US TMS market space * DEEP TMS vs. TRADITIONAL “FIGURE - 8” TMS

  6. Slide 6: From 24M Sufferers to ~8.5M Eligible Patients

    Slide 6: From 24M Sufferers to ~8.5M Eligible Patients

    T H E M A R K E T O P P O R T U N I T Y From 24M Sufferers to ~8.5M Eligible Patients The treatment - resistant population across BrainsWay's two largest FDA - cleared indications — U.S. patients who have already failed conventional care. M A J O R D E P R E S S I V E D I S O R D E R 21M U.S. clinic

  7. Slide 7: Every Success Creates the Next Layer of Growth

    Slide 7: Every Success Creates the Next Layer of Growth

    T H E G R O W T H F L Y W H E E L Every Success Creates the Next Layer of Growth Every turn does three things — grows organic demand, raises barriers to entry, and funds expansion. Self - reinforcing growth engine 1 Increasing Organic Growth Increased access — more patient starts at low incremental

  8. Slide 8: A Model Built to Compound — With Clear Line of Sight

    Slide 8: A Model Built to Compound — With Clear Line of Sight

    B U S I N E S S M O D E L & V I S I B I L I T Y A Model Built to Compound — With Clear Line of Sight Every system becomes a long - term asset — a one - time hardware sale transformed into high - margin, multi - year recurring revenue. 4 - 5 Yrs Multi - year leasing Typical contract term (4 – 5 yr).

  9. Slide 9: Why Clinics Keep Expanding

    Slide 9: Why Clinics Keep Expanding

    C U S T O M E R E C O N O M I C S Why Clinics Keep Expanding One chair leads to a second, then a third, then a second clinic — compelling economics drive enterprise - wide rollout. SINGLE - CHAIR ECONOMICS ~$0.8M - $1M Annual revenue per chair ~$0.5M - 0.7M Profit per chair, per year Rapid Cash - on

  10. Slide 10: The SWIFT Advantage: From 20 Days to 6 Days

    Slide 10: The SWIFT Advantage: From 20 Days to 6 Days

    T H E S W I F T A D V A N T A G E From 20 Days to 6 Days The only FDA - cleared 6 - day accelerated Deep TMS protocol — a significantly faster path to relief. S T AN D AR D P R O T O C O L 20 days Treatment days in the acute phase – before maintenance S W I F T P R O T O C O L 6 days Only 6 treatmen

  11. Slide 11: Strategic Partnership With Valor Equity Partners

    Slide 11: Strategic Partnership With Valor Equity Partners

    Strategic Partnership With Valor Equity Partners 11 Investor Deck | November 2026 Valor, a leading $20B equity firm behind market leaders, is now BrainsWay’s largest investor and an active partner in our scale strategy

  12. Slide 12: Strategic Investments: A Low-Risk, High-ROI Network

    Slide 12: Strategic Investments: A Low-Risk, High-ROI Network

    S T R A T E G I C I N V E S T M E N T S A Low - Risk, High - ROI Network That Widens the Moat Low - risk and capital - light with high ROI — equity stakes deepen partnerships, expand patient access, and widen our competitive moat. BACKED BY Valor Equity Partners A ~$100B firm and BrainsWay's largest

  13. Slide 13: A Pipeline of Expanding Indications

    Slide 13: A Pipeline of Expanding Indications

    T H E P I P E L I N E A Pipeline of Expanding Indications New potential FDA indications can expand the addressable market on the same commercial platform 1 CLEARED TODAY 4 FDA Indications MDD, OCD, smoking addiction and anxious depression — a proven regulatory track record. › 2 PIPELINE Alcohol Use

  14. Slide 14: A Multi-Billion-Dollar International Opportunity

    Slide 14: A Multi-Billion-Dollar International Opportunity

    G L O B A L E X P A N S I O N A Multi - Billion - Dollar International Opportunity We are not entering these markets — we are scaling established commercial partnerships across regions with hundreds of millions 9 of untreated patients. 37M Europe 71M China 6M Japan 57M India 1.3M Australia 170 M + 1

  15. Slide 15: Extending to Home-Use Neuromodulation

    Slide 15: Extending to Home-Use Neuromodulation

    Extending to Home - Use Neuromodulation • RELIVION® PATIENT REMOTE MANAGEMENT INTERFACE Proliv Rx Cloud BIG DATA ANALYTICS Physician Remotely monitors patient Proliv Rx Patient’s App Uploads data Remote Monitoring & Big Data Analytics $11M convertible debt; milestone tranches; call option to acquire

  16. Slide 16: Financial Results Validate the Thesis

    Slide 16: Financial Results Validate the Thesis

    9 M O U N T H S 2 0 2 6 P E R F O R M A N C E Financial Results Validate the Thesis Strong year - to - date growth is translating into higher margins, profitability, and cash generation. R E V E N U E $50.8M +35% year - over - year A D J U S T ED EB I T D A $10.2M +114% year - over - year 76% Gross

  17. Slide 17: Revenue Growing Far Faster Than Costs

    Slide 17: Revenue Growing Far Faster Than Costs

    Revenue Growing Far Faster Than Costs 40 53 73 90 32 41 51 70 28 29 36 42 - 2 5 7 14 2023 2026E 2024 Bookings Revenue OPEX 2025 Adj. EBITDA Revenue +30 - 34% growth OPEX <18% growth Adj. EBITDA $ in millions 17 O P E R A T I N G L E V E R A G E *Adjusted EBITDA is a Non - IFRS Measure. See operating

  18. Slide 18: The Investment Case: Why BrainsWay, Why Now

    Slide 18: The Investment Case: Why BrainsWay, Why Now

    Investor Deck | November 2026 T H E I N V E S T M E N T C A S E Why BrainsWay, Why Now 01 The market is inflecting. Interventional psychiatry is going mainstream. 02 BrainsWay leads. The only Deep TMS platform with 4 FDA indications. 03 The economics compound. Strong recurring revenue, 90%+ retentio

  19. Slide 19: Building the Global Platform for Interventional Psychiatry

    Slide 19: Building the Global Platform for Interventional Psychiatry

    Building the Global Platform for Interventional Psychiatry. One Platform Millions of Patients Decades of Growth N A S D A Q / T A S E : B W A Y 19

  20. Slide 20: References

    Slide 20: References

    Investor Deck | November 2026 References 1. Data on file 2. See company reimbursement database ; published payer policies ; and sec . gov/Archives/edgar/data/ 1735948 / 000110465921043982 /tm 2111152 d 1 _ex 99 - 1 . htm 3. BrainsWay Data on File ; Depth, measured in phantom head, is from cortical s

Source: SEC EDGAR · 6-K filed Nov 10, 2026

More decks from BrainsWay Ltd

All 12 BrainsWay decks